Home | Cancer | Leukemia-lymphoma-cancer
The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in OncologyTM for Chronic Myelogenous Leukemia (CML). These changes highlight leading developments in the treatment of CML and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings. A panel of world-renowned experts added Dasatinib (Sprycel, Bristol-Myers Squibb) to the guideline. Dasatinib, a new tyrosine kinase inhibitor, is approved by the FDA for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy, including imatinib. It is also approved for Philadelphia-chromosome positive acute lymphoblastic leukemia. The NCCN guidelines include dasatinib as a treatment recommendation at specific follow-up evaluation periods for patients that relapse or did not respond to imatinib therapy, or who have disease progression on imatinib therapy. The panel also added indications for cytogenetics and mutation analysis for patients receiving imatinib therapy and an 18-month follow-up evaluation with treatment recommendations based upon cytogenetic response. NCCN Clinical Practice Guidelines in OncologyTM are developed and updated through a consensus-driven process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN member institutions. The most recent version of this and all the guidelines are available for free at www.nccn.org. For more information, please contact Thomas Mitchell or visit www.nccn.org. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. The NCCN member institutions are: City of Hope Cancer Center, Los Angeles, CA; Dana-Farber/Partners CancerCare, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; and The University of Texas M. D. Anderson Cancer Center, Houston, TX.
Article Source: http://www.content.onlypunjab.com
For more information, visit www.nccn.org.
Please Rate this Article
5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
